Vera Therapeutics Announces TRUTAKNA (Atacicept-Vymj) Commercial Launch Details Following July 7 FDA Accelerated Approval: $425,000 Per Year List Price for the BAFF/APRIL-Targeting Peptide-and-Fc Fusion Protein, 82 Sales Representatives Deployed at Launch, In-Channel Pharmacy Availability Within Three to Four Weeks, and Ongoing ORIGIN 3 Confirmatory Trial (Blinded Placebo-Controlled eGFR Endpoint) With Results Anticipated in Q3 2026 That Will Determine Whether the Accelerated Approval Converts to Traditional Approval
Vera Therapeutics (NASDAQ: VERA) confirmed commercial-launch parameters for TRUTAKNA (atacicept-vymj) following the July 7, 2026 FDA accelerated approval for adults with primary IgA nephropathy at risk of rapid disease progression. List price: $425,000 per year for the recombinant peptide-and-Fc fusion protein (TACI extracellular domain fused to human IgG1 Fc). Sales force: 82 representatives deployed at launch. Distribution: in-channel pharmacy availability within three to four weeks of approval, with insurance coverage under specialty-pharmacy medical benefit pathways given the subcutaneous injection administration. The July 7 accelerated approval was based on the Phase 3 ORIGIN study 36-week urine protein-to-creatinine ratio (UPCR) endpoint (45.7% reduction versus 6.8% for standard of care). Continued FDA approval may be contingent on verification of clinical benefit in the ongoing ORIGIN 3 confirmatory trial, which continues in a placebo-controlled blinded manner to evaluate change in kidney function as measured by estimated glomerular filtration rate (eGFR); results are anticipated in Q3 2026. If the ORIGIN 3 eGFR data hit, TRUTAKNA converts to traditional approval on the harder outcome endpoint.